search
Back to results

Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee

Primary Purpose

Osteoarthritis, Knee

Status
Withdrawn
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
YY1201 2ml
Placebo 2ml
YY1201 3ml
Placebo 3ml
Sponsored by
Yooyoung Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Osteoarthritis

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Males or Females 40 years and older
  2. According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings.

    • Over 50 years of age
    • Less than 30 minutes of morning stiffness
    • Crepitus on active motion
    • 4 bony tenderness
    • Bony enlargement
    • Nopalpable warmth of synvium
  3. Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination.
  4. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm
  5. Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past.
  6. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.)
  7. Patient who agrees to participate in this clinical trial by themselves.

Exclusion Criteria:

  1. Someone who has BMI≥32kg/m² at the screening visit.
  2. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually.
  3. Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period.
  4. Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine).
  5. Patient who has rheumarthritis or other inflammatory metabolic arthritis.
  6. Patients having serious gastrointestinal, liver, renal, heart disease.
  7. When the inflammatory disease is occurred on joint area to patient like septic arthritis.
  8. Patients having skin ailment at the injecting site of the joint region.
  9. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease.
  10. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation.
  11. Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain.
  12. Patients who diagnosed clear interval disappearance at the knee joint by X-ray.
  13. Patients who were administrated below drugs before baseline visit.

    • Patients who were injected HA at the target knee joint in recent 9 months.
    • Patients who were injected HA at other parts of the knee joint in recent 6 months.
    • Patients who were injected steroids into the intra-articular knee joint.
    • Patients who were administrated steroids systemically by the oral medication (But, except inhalation)
  14. Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test.
  15. Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal.
  16. Patients who have an operation history about target knee joint.
  17. Patients who do the height weight aerobic exercise or anaerobic exercise.
  18. Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin)
  19. Patients who have hypersensitivity history about Investigational Product.
  20. In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product.

    * The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc.

  21. Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail.
  22. Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision.

Sites / Locations

  • Samsung Medical Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Arm Label

YY1201 2ml

YY1201 3ml

Placebo 2ml

Placebo 3ml

Arm Description

YY1201 2ml

YY1201 3ml

Phosphate buffered saline 2ml

Phosphate buffered saline 3ml

Outcomes

Primary Outcome Measures

Variation of the Weight-bearing pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline

Secondary Outcome Measures

Variation of the KOOS scales on the 4, 12 weeks after administration in comparison with baseline
Variation of the rest pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Motion pain (100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Patient global assessment (100mm-VAS) on the 4, 12 weeks after administration with baseline
Investigator global assessment (100mm-VAS) on the 4, 12 weeks after administration
Change of the swelling in the knee joint from baseline to 4, 12 weeks after administration
Change of the tenderness on pressure in the knee joint from baseline to 4, 12 weeks after administration
Rate of change of the Range Of Motion(ROM) in the knee joint on 4, 12 weeks after administration with baseline
Use of rescue medication count and the total amount on 4, 12 weeks
Response rate of the Weight-bearing pain on 12 weeks in comparison with baseline
Response rate of the OMERACT-OARSI on 12 weeks in comparison with baseline

Full Information

First Posted
September 15, 2015
Last Updated
November 15, 2016
Sponsor
Yooyoung Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT02554552
Brief Title
Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee
Official Title
A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Withdrawn
Why Stopped
This study has been withdrawn prior to enrollment.
Study Start Date
September 2015 (undefined)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
October 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Yooyoung Pharmaceutical Co., Ltd.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, randomized, double-blinded, parallel, placebo-controlled, phase I/IIa clinical trial of YY1201 for treatment of osteoarthritis of the knee.
Detailed Description
phase I/IIa clinical trial of YY1201 for treatment of osteoarthritis of the knee

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis, Knee
Keywords
Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
YY1201 2ml
Arm Type
Experimental
Arm Description
YY1201 2ml
Arm Title
YY1201 3ml
Arm Type
Experimental
Arm Description
YY1201 3ml
Arm Title
Placebo 2ml
Arm Type
Placebo Comparator
Arm Description
Phosphate buffered saline 2ml
Arm Title
Placebo 3ml
Arm Type
Placebo Comparator
Arm Description
Phosphate buffered saline 3ml
Intervention Type
Drug
Intervention Name(s)
YY1201 2ml
Intervention Description
YY1201 2ml
Intervention Type
Drug
Intervention Name(s)
Placebo 2ml
Other Intervention Name(s)
Placebo comparator 1
Intervention Description
phosphate buffered saline 2ml
Intervention Type
Drug
Intervention Name(s)
YY1201 3ml
Intervention Description
YY1201 2ml
Intervention Type
Drug
Intervention Name(s)
Placebo 3ml
Other Intervention Name(s)
Placebo comparator 2
Intervention Description
phosphate buffered saline 3ml
Primary Outcome Measure Information:
Title
Variation of the Weight-bearing pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Time Frame
Week 4 and Week 12
Secondary Outcome Measure Information:
Title
Variation of the KOOS scales on the 4, 12 weeks after administration in comparison with baseline
Time Frame
Week 4 and Week 12
Title
Variation of the rest pain(100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Time Frame
Week 4 and Week 12
Title
Motion pain (100mm-VAS) on the 4, 12 weeks after administration in comparison with baseline
Time Frame
Week 4 and Week 12
Title
Patient global assessment (100mm-VAS) on the 4, 12 weeks after administration with baseline
Time Frame
Week 4 and Week 12
Title
Investigator global assessment (100mm-VAS) on the 4, 12 weeks after administration
Time Frame
Week 4 and Week 12
Title
Change of the swelling in the knee joint from baseline to 4, 12 weeks after administration
Time Frame
Week 4 and Week 12
Title
Change of the tenderness on pressure in the knee joint from baseline to 4, 12 weeks after administration
Time Frame
Week 4 and Week 12
Title
Rate of change of the Range Of Motion(ROM) in the knee joint on 4, 12 weeks after administration with baseline
Time Frame
Week 4 and Week 12
Title
Use of rescue medication count and the total amount on 4, 12 weeks
Time Frame
Week 4 and Week 12
Title
Response rate of the Weight-bearing pain on 12 weeks in comparison with baseline
Time Frame
Week 12
Title
Response rate of the OMERACT-OARSI on 12 weeks in comparison with baseline
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Males or Females 40 years and older According to the clinical diagnosis standard of the American College of Rheumatology (ACR), someone, diagnosed as a single/both sides of osteoarthritis, who corresponds to over 3 conditions of followings. Over 50 years of age Less than 30 minutes of morning stiffness Crepitus on active motion 4 bony tenderness Bony enlargement Nopalpable warmth of synvium Within 6 months from screening visit, someone who diagnosed with Kellgren & Lawrence Grade I~III by the radioactive examination. By the Weight-bearing pain(100mm-VAS) examination, someone who has a outcome of the single or both sides of the osteoarthritis is over 40mm Patient (No-responder) who has experienced steady pain in spite of dosing NSAIDs or other pain-killers in the past. Patient who can walk by themselves without helper like cane or walker etc. (If the patient who has used helper routinely from previous 6 months, evaluating the patient including the helper is possible. In this case, patient needs to use same helper continuously by end of the clinical trial test.) Patient who agrees to participate in this clinical trial by themselves. Exclusion Criteria: Someone who has BMI≥32kg/m² at the screening visit. Patient who has an experience dosing psychoactive drug, narcotic analgesic which can have an effect on pain sense over 3 months habitually. Patient who has been administrated gastrointestinal drug(for example H₂-blockers, misoprostol or proton pump inhibitors) regularly, who can't stop injecting for clinical study period. Patient has attended abnormal values from screening test(2 times excess at upper limit of the normal values at ALT, AST, BUN, Serum Creatinine). Patient who has rheumarthritis or other inflammatory metabolic arthritis. Patients having serious gastrointestinal, liver, renal, heart disease. When the inflammatory disease is occurred on joint area to patient like septic arthritis. Patients having skin ailment at the injecting site of the joint region. Patients having secondary osteoarthritis according to the Ochronosis, Hemochromatosis or systemic disease. Patients who have severe pain like Sudek's atrophy, Paget's disease, Spinal disc herniation. Poly-articular patients who have suffered seriously by osteoarthritis at other parts affect judge of the knee joint pain. Patients who diagnosed clear interval disappearance at the knee joint by X-ray. Patients who were administrated below drugs before baseline visit. Patients who were injected HA at the target knee joint in recent 9 months. Patients who were injected HA at other parts of the knee joint in recent 6 months. Patients who were injected steroids into the intra-articular knee joint. Patients who were administrated steroids systemically by the oral medication (But, except inhalation) Patients who have joint effusion trouble were judged as a positive by tests like Patella tap test. Patients who have target knee joint gotten surgical operation history including Arthroscopy within past one year (In case of having other side of knee joint or hip joint gotten surgical operation history, excepting the patients if there is possibility which can influence the target knee joint's appraisal. Patients who have an operation history about target knee joint. Patients who do the height weight aerobic exercise or anaerobic exercise. Patients who need to be administrated anticoagulant agent together(But, except 300mg daily dose aspirin) Patients who have hypersensitivity history about Investigational Product. In the midst of women in their childbearing years, patients who disagree to do * contraception by medically permitted method for 12 weeks from administrating investigational product. * The contraception by medically permitted method: Condom, In case of using injection or insertion, In case of installing a intrauterine contraception device etc. Patients who were injected other investigational product over a time within 30 days before participated in this clinical trail. Besides that, the patients who have difficulty to be participated in this clinical trial continuously by Principle Investigator (PI)'s decision.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chul-Won Ha, M.D.
Organizational Affiliation
Samsung Medical Center, Department of Internal Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Samsung Medical Center
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee

We'll reach out to this number within 24 hrs